Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~A subject will be eligible for inclusion in this study only if all of the following criteria apply:~1. Male or female 18 years of age and over.~2. Inpatient or outpatient with a diagnosis of cancer.~3. Stable but inadequately controlled pain with current therapy for at least two weeks.~4. Experiencing somatic, visceral and/or neuropathic pain related to cancer.~5. Baseline pain intensity, as assessed by Question #3 of the Brief Pain Inventory (BPI) that meets the definition of moderate (score of 4-5) or severe (score of 6-10) pain.~6. Life expectancy of at least 3 months.~7. Ability to communicate well with the investigator and to comply with the requirements (restrictions, appointments, and examination schedule) of the entire study.~8. Signed informed consent document (prior to any study-related procedures being performed).~Exclusion criteria~A subject will not be eligible for inclusion in this study if any of the following criteria apply:~1. Planned initiation of chemotherapy, radiotherapy, or bisphosphonates within 30 days prior to randomization.~2. Use of anaesthetics.~3. Use of lidocaine and other types of antiarrhythmic drugs.~4. Use of scopolamine and acetylcholinesterase-inhibiting drugs such as physostigmine.~5. History of CO2 retention, or SaO2 \<80% either on room air or O2 of not greater than 2-4 L/min by nasal cannula.~6. Second- or third-degree heart block or prolonged QTc interval (corrected for rate) on screening ECG (confirmed \> 450 msec on repeated occasion) or any other active cardiac arrhythmia or abnormality that could constitute a clinical risk.~7. Coagulation or bleeding defects if, in the opinion of the investigator, this represents a risk to the subject considering the subcutaneous (s.c.) route of administration.~8. Known hypersensitivity to puffer fish, tetrodotoxin and/or its derivatives.~9. Use of an investigational agent within 30 days prior to screening or is scheduled to receive an investigational drug other than tetrodotoxin during the course of the study.~10. Females who are lactating or at risk of pregnancy (i.e., sexually active with fertile males and not using an adequate form of birth control).~11. Females with a positive serum pregnancy test at screening or positive urine pregnancy test on admission to study site.~12. Any other condition that, in the opinion of the investigators, is likely to interfere with the successful collection of the measures required for the study or poses a risk to the patient.~13. Men with glomerular filtration rate (GRF) less than 60 mL/min/1.73 m2 and women with GFR less than 50 mL/min/1.73 m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tetrodotoxin (Type: ACTIVE_COMPARATOR): None
- Sugar injection (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).